Literature DB >> 1357134

Effect of oily vehicles on absorption of mepitiostane by the lymphatic system in rats.

T Ichihashi1, H Kinoshita, Y Takagishi, H Yamada.   

Abstract

[14C]Mepitiostane in various vehicles was administered to the small intestine of anaesthetized rats with cannulated thoracic ducts, and the effect of lipids on lymphatic absorption was examined. The extent of lymphatic absorption was greatest when administered in triolein and sesame oil, which are triglycerides of long-chain fatty acids. Absorption in the presence of other vehicles was in the order of 10% Tween 80 aqueous solution greater than monolein greater than oleic acid approximately oleic acid/monolein (2:1 mol/mol) greater than aqueous suspension. Differences between the extents of lymphatic absorption of mepitiostane in the various formulations were not due to variation in the lymph flow but to the increased secretion of chylomicron and very low density lipoproteins. During absorption of mepitiostane from the small intestine, oil affected not only the penetration into epithelium cells and the metabolism in them, but also the partition between blood and lymph.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1357134     DOI: 10.1111/j.2042-7158.1992.tb05464.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  3 in total

1.  Comparison of the lymphatic transport of halofantrine administered in disperse systems containing three different unsaturated fatty acids.

Authors:  R Holm; A Müllertz; G P Pedersen; H G Kristensen
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

Review 2.  Intestinal lymphatic transport for drug delivery.

Authors:  Jaime A Yáñez; Stephen W J Wang; Ian W Knemeyer; Mark A Wirth; Kevin B Alton
Journal:  Adv Drug Deliv Rev       Date:  2011-06-13       Impact factor: 15.470

Review 3.  Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update.

Authors:  Natalie L Trevaskis; William N Charman; Christopher J H Porter
Journal:  Adv Drug Deliv Rev       Date:  2007-11-07       Impact factor: 15.470

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.